Reports
Sale
Global Influenza Medication Market Share, Trends, Research: By Type: Antiviral Drugs, Antihistamines, Vaccines, Others; By Influenza Type: Influenza A, Influenza B, Others; By Route of Administration: Oral, Others; By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Influenza Medication Market Outlook
The global influenza medication market size reached a value of USD 1,033.06 million in 2023, driven by the increasing cases of influenza and active healthcare systems engaged in combating influenza worldwide. The market is anticipated to grow at a CAGR of 3.4% during the forecast period of 2024-2032 to attain a value of USD 1,400.62 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Influenza Medication: Introduction and Insights
Influenza is a viral infection that spreads easily and can prove to be fatal at times, due to which there is a strong demand for the influenza medication market. It is usually self-diagnosable and resolves within days or weeks. It spreads through skin-to-skin contact, contact with the saliva of an infected person, by touching a contaminated surface or by airborne respiratory droplets. One can prevent it by taking a vaccine annually. For treatment, rest and fluid intake are considered primary which allows the body to fight the infection on its own.
- There has been significant success in understanding the Influenza virus and developing remedies to treat them. However, most significant of all the treatments is vaccination. The Human Vaccines Project started the Universal Influenza Vaccine Initiative in collaboration with various private and government sectors to speed the development of the influenza vaccine.
- Four authorised antiviral developments ‘Oseltamivir', ‘Zanamivir', ‘Amantadine', and ‘Rimantadine' are likely to rise in the influenza medication market during the forecast period because no other trial could compete with their effectiveness in treatment. Amantadine and Rimantadine reduce the duration of influenza and treat type A infection while Oseltamivir and Zanamivir are neuraminid inhibitors.
- Increase in the number of affected people by influenza will ultimately steer the demand for influenza drugs all around the globe. Older people who are more prone to this sickness is yet another reason that will surge the demand for influenza medications. This will increase the emphasis on research which will help in better development of treatment protocols, making it a lucrative opportunity for the market to grow.
Recent Drug Approvals in the Influenza Medication Market
In August 2023, Genentech announced that United States’ FDA approved for the use of ‘Xofluza’. It acts as influenza medication for children aged 5 years and older. It is the first-in-class and only single-dose oral medicine that has been approved for children as young as 5 years old. Before the FDA approval was announced, it was used to treat flu in people who have had symptoms for not more than 48 hours and was used only for children aged 12 years and older.
In August 2023, UZ Leuven and KU Leuven carried out a trial with international partners and discovered that patients with influenza or COVID-19 also develop an additional fungal infection ‘aspergillosis' along with various other tissue damage. This study will make way for the development of modified remedies for patients with this double infection, extending the reach of the influenza medication market.
In July 2023, Seqirus and a business of CSL Limited (ASX: CSL) partnered for multi-year influenza medication research with the University of Liverpool Pandemic Institute. Seqirus would participate in research projects and inform the generation of the threat of seasonal influenza and develop innovative approaches to the pandemic response.
In April 2023, a new influenza vaccine was developed against a pandemic variant of the H5N1 subunit virus. The vaccine has proved to be highly immunogenic in both younger and the older generations. This virus is mainly found in wild and domestic birds and poultry. Humans are as of now unaffected by this virus, but if it were to affect humans, public health could be severely affected and so the vaccine was developed.
Influenza Medication Market Segmentations
The market can be categorised into segments like type, influenza type, route of administration, distribution channels, and major regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
- Antiviral Drugs
- Antihistamines
- Vaccines
- Others
Market Breakup by Influenza Type
- Influenza A
- Influenza B
- Others
Market Breakup by Route of Administration
- Oral
- Others
Market Breakup by Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Influenza Medication Market Breakup by Regions
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Influenza Medication Market Scenario
Influenza medication products are distributed through various channels, including hospital pharmacies and retail pharmacy stores. With growing technology, they can be easily availed online as well. Hospital pharmacies hold a dominant share in the market because better care is taken, and treatment is conducted along with medication at the hospital itself through stronger medications which are generally unavailable in the retail market.
However, the retail market provides maximum medications in the oral form which are easy to self-administer. Convenient availability of medications online increases its long-term potential as compared to the hospital pharmacy segment. Retail pharmacies, on the other hand, are anticipated to hold the second largest share in the influenza medication market.
North America has been dominating the market and is expected to do the same in the future because of the increase in the medications launched in the region. The Asia Pacific is expected to give a tough competition to North America in the forecast period. Countries, including the United Kingdom, France, and Germany contribute to the growth of the European market.
The increasing status of influenza has overall affected the growth of the influenza medication market. That is because there is a rapid growth in influenza, ultimately increasing the mortality rate, thus bolstering the demand for the medication overall and affecting the market.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global influenza medication market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Genentech, Inc.
- Shionogi and Co., Ltd.
- Seqirus Inc.
- AstraZeneca PLC
- Novartis AG
- GlaxoSmithKline Plc
- Lupin Limited
- Biocrystal Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Zydus Pharmaceuticals, Inc.
- Amneal Pharmaceutical LLC
- Macleods Pharmaceuticals Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Influenza Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Influenza Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Influenza Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Influenza Epidemiology (2016-2031)
5.3 Europe Influenza Epidemiology (2016-2031)
5.4 Asia-Pacific Influenza Epidemiology (2016-2031)
5.5 Latin America Influenza Epidemiology (2016-2031)
5.6 Middle East & Africa Influenza Epidemiology (2016-2031)
6 Global Influenza Medication Market Overview
6.1 Global Influenza Medication Market Historical Value (2017-2023)
6.2 Global Influenza Medication Market Forecast Value (2024-2032)
7 Global Influenza Medication Market Landscape
7.1 Global Influenza Medication: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Influenza Medication: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Influenza Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Distribution Channel
8 Influenza Medication Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Influenza Medication Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Influenza Medication Market Segmentation
11.1 Global Influenza Medication Market by Type
11.1.1 Market Overview
11.1.2 Antiviral Drugs
11.1.3 Antihistamines
11.1.4 Vaccines
11.1.5 Others
11.2 Global Influenza Medication Market by Influenza Type
11.2.1 Market Overview
11.2.2 Influenza A
11.2.3 Influenza B
11.2.4 Others
11.3 Global Influenza Medication Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Others
11.4 Global Influenza Medication Market by Distribution Channels
11.4.1 Market Overview
11.4.2 Hospital Pharmacies
11.4.3 Retail Pharmacies
11.4.4 Online Pharmacies
11.4.5 Others
11.5 Global Influenza Medication Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Influenza Medication Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Influenza Medication Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Influenza Medication Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Influenza Medication Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Influenza Medication Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Shionogi and Co., Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Seqirus Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 AstraZeneca PLC
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Novartis AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline Plc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Lupin Limited
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Biocrystal Pharmaceuticals, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Teva Pharmaceutical Industries Ltd.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Zydus Pharmaceuticals, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Amneal Pharmaceutical LLC
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Macleods Pharmaceuticals Ltd.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Global Influenza Medication Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 1,033.06 million in 2023. The growth drivers include the increasing cases of influenza and active healthcare systems engaged in combating influenza worldwide.
The market is anticipated to grow at a CAGR of 3.4% during the forecast period of 2024-2032 to attain a value of USD 1,400.62 million by 2032.
It spreads through skin-to-skin contact, exposure, contact to saliva, or by touching a contaminated surface or by airborne respiratory droplets.
Amantadine and Rimantadine are common medications known to reduce the duration of influenza in humans.
The regional markets include North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
The types of medications in the market include antiviral drugs, antihistamines, and vaccines, among others.
The types can be categorised into influenza A and B, among others. Influenza A is the most common type of influenza.
The routes of administration include oral routes, among others.
The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The key players in the market include Genentech, Inc., Shionogi and Co., Ltd., Seqirus Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline Plc, Lupin Limited, Biocrystal Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., and Amneal Pharmaceutical LLC.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER